Developer docs
API playgroundTry for free, no card

Search company profiles

PostEra

Full company profile

uuid0000qrh

Namestring
PostEra
Legal namestring
PostEra
Websiteurl
postera.ai
Company typeenum
Private
Founded yearint
2019
Descriptiontext

PostEra is an AI-driven biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2019 by Aaron Morris (CEO), Alpha Lee (CSO), and Matthew Robinson (CTO). The company has developed Proton, an end-to-end machine learning platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary chemistry data with chemistry foundation models to design molecules, employs state-of-the-art synthesis planning to ensure every designed molecule has a reliable synthetic route, and uses novel active learning methodologies to select the most informative experiments at each cycle. A reported 40% faster stage-gate achievement on a Pfizer AI Lab program indicates the platform can materially compress medicinal chemistry timelines.

PostEra commercializes Proton through two channels. First, it runs co-discovery partnerships with major pharmaceutical companies — notably Pfizer (AI Lab formed 2021, expanded to $610M in 2025 including ADC programs), Amgen (multi-program agreement, contributing to over $1B in cumulative AI drug discovery partnerships), and NIH ($68M antiviral grant) — where the partner selects biological targets and PostEra drives discovery through Development Candidate nomination. Second, PostEra advances a wholly-owned preclinical pipeline in women's health indications including PCOS, reproductive endocrinology, and fertility. The company also led COVID Moonshot, described as the world's largest open-science drug discovery effort.

Revenue mechanics are enterprise-style and milestone-weighted: multi-year contracts with upfront payments, research funding, development/regulatory/commercial milestone payments, and royalties on commercialized products, supplemented by government grant funding such as the NIH antiviral program. Equity capital is modest (a $24M Series A led by Clermont Group in 2021/2022, total disclosed equity around $26M, with Y Combinator as an early backer), while cumulative contracted partnership value exceeds $1 billion.

Short descriptiontext

PostEra is an AI-driven biopharmaceutical company that uses its Proton machine learning platform to accelerate medicinal chemistry, running co-discovery partnerships with major pharmaceutical companies (Pfizer, Amgen, NIH) and a wholly-owned women's health pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, medicinal chemistry, machine learning platform, small molecule therapeutics, preclinical drug discovery
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Partnerships
TypeSubscription Recurring
Description

Multi-year strategic collaborations with major pharmaceutical companies including Pfizer and Amgen. Revenue comes from upfront payments, research funding, milestone payments (development, regulatory, and commercial), and royalties on approved products. The expanded Pfizer collaboration is valued at $610M including additional programs in antibody-drug conjugates.

xyzeo.com
2Government Research Grants
TypeSubscription Recurring
Description

NIH-funded research collaboration for antiviral therapeutics. Initial funding of $68 million to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.

en.prnasia.com
3Equity Financing
TypeLicensing Royalties
Description

Venture capital funding including $24 million equity financing led by the Clermont Group. Used to enhance drug discovery programs and develop the AI-driven medicinal chemistry platform.

aithority.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Enterprise pharmaceutical partnerships
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Multi-year strategic collaborations with pharmaceutical companies including upfront payments, milestone payments tied to development stages (IND-enabling, clinical, regulatory), and royalty payments on commercialized products. Pfizer collaboration expanded to $610M total deal value; Amgen multi-program agreement; NIH grant $68M for antivirals.

xyzeo.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

PostEra develops and applies Proton, its proprietary end-to-end machine learning platform for medicinal chemistry, to accelerate small molecule drug discovery. Through the platform the company runs co-discovery collaborations with major pharmaceutical companies (Pfizer, Amgen) and government agencies (NIH) and advances a wholly-owned preclinical pipeline in women's health (PCOS, reproductive endocrinology, fertility). Revenue is generated via multi-year partnerships with upfront payments, milestones, and royalties, supplemented by government grants.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • One AI Lab program achieved its first scientific stage gate 40% faster than initially forecasted
+1 more record
Product overview1 text field

PostEra operates as an AI-driven biopharmaceutical company built around its Proton Platform—an end-to-end machine learning platform for medicinal chemistry. The company advances drug discovery through two channels: (1) a wholly-owned internal pipeline targeting women's health indications (PCOS, reproductive endocrinology, fertility), and (2) partnered programs with major pharmaceutical companies (Pfizer, Amgen, NIH) using Proton to discover small molecule therapeutics across oncology, obesity, antivirals, and antibody-drug conjugates. PostEra also led COVID Moonshot, the world's largest open-science drug discovery initiative. The company has secured over $1 billion in partnerships and is backed by Y Combinator.

Product and service2 records
1Proton Platform
CategoryCore platform / AI drug discovery software
Description

End-to-end AI platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary data with chemistry foundation models to design molecules, applies state-of-the-art synthesis planning to ensure reliable synthetic routes, and uses active learning methodologies to gather informative data at each cycle. Used by PostEra both to run partnered co-discovery programs with biopharma and to advance the company's internal drug pipeline.

2COVID Moonshot
CategoryOpen-science drug discovery initiative
Description

Open-science, community-driven antiviral drug discovery program using PostEra's AI capabilities to crowdsource compound design, synthesis, and testing for COVID-19 therapeutics. Demonstrates the application of Proton outside of conventional biopharma partnerships and produces openly shared data for the research community.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-07
Description

Expanded AI drug discovery collaboration to $610 million total deal value, adding antibody-drug conjugates (ADCs) to the partnership. Includes AI Lab formed in 2021 for multi-target collaboration and additional ADC programs in 2025. PostEra uses its Proton platform to accelerate multiple preclinical drug discovery programs with additional payments and milestones. One program achieved first stage gate 40% faster than forecasted; Pfizer nominated a third target into the AI Lab in 2024.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Multi-program agreement as part of PostEra's $1 billion+ in AI drug discovery collaborations. Collaboration focused on small molecule drug discovery using PostEra's Proton platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-01
Description

Multi-year AI-driven drug discovery collaboration for antiviral therapeutics with $68 million initial funding. The initiative aims to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a Drug Discovery Partner on PostEra's website, indicating academic collaboration for drug discovery research.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles27 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PostEra

AI Drug Discovery Platformpostera.ai

PostEra is an AI-driven biopharmaceutical company that uses its Proton machine learning platform to accelerate medicinal chemistry, running co-discovery partnerships with major pharmaceutical companies (Pfizer, Amgen, NIH) and a wholly-owned women's health pipeline.

What PostEra does

PostEra is an AI-driven biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2019 by Aaron Morris (CEO), Alpha Lee (CSO), and Matthew Robinson (CTO). The company has developed Proton, an end-to-end machine learning platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary chemistry data with chemistry foundation models to design molecules, employs state-of-the-art synthesis planning to ensure every designed molecule has a reliable synthetic route, and uses novel active learning methodologies to select the most informative experiments at each cycle. A reported 40% faster stage-gate achievement on a Pfizer AI Lab program indicates the platform can materially compress medicinal chemistry timelines.

PostEra commercializes Proton through two channels. First, it runs co-discovery partnerships with major pharmaceutical companies — notably Pfizer (AI Lab formed 2021, expanded to $610M in 2025 including ADC programs), Amgen (multi-program agreement, contributing to over $1B in cumulative AI drug discovery partnerships), and NIH ($68M antiviral grant) — where the partner selects biological targets and PostEra drives discovery through Development Candidate nomination. Second, PostEra advances a wholly-owned preclinical pipeline in women's health indications including PCOS, reproductive endocrinology, and fertility. The company also led COVID Moonshot, described as the world's largest open-science drug discovery effort.

Revenue mechanics are enterprise-style and milestone-weighted: multi-year contracts with upfront payments, research funding, development/regulatory/commercial milestone payments, and royalties on commercialized products, supplemented by government grant funding such as the NIH antiviral program. Equity capital is modest (a $24M Series A led by Clermont Group in 2021/2022, total disclosed equity around $26M, with Y Combinator as an early backer), while cumulative contracted partnership value exceeds $1 billion.

PostEra firmographics

Firmographics
Name
PostEra
Legal name
PostEra
Website
https://postera.ai
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
PostEra is an AI-driven biopharmaceutical company that uses its Proton machine learning platform to accelerate medicinal chemistry, running co-discovery partnerships with major pharmaceutical companies (Pfizer, Amgen, NIH) and a wholly-owned women's health pipeline.
Ownership category
akta.pro rank

PostEra industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Medicinal chemistry
  • Machine learning platform
  • Small molecule therapeutics
  • Preclinical drug discovery

Where PostEra is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

PostEra business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Partnerships: Multi-year strategic collaborations with major pharmaceutical companies including Pfizer and Amgen. Revenue comes from upfront payments, research funding, milestone payments (development, regulatory, and commercial), and royalties on approved products. The expanded Pfizer collaboration is valued at $610M including additional programs in antibody-drug conjugates.
  2. Government Research Grants: NIH-funded research collaboration for antiviral therapeutics. Initial funding of $68 million to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.
  3. Equity Financing: Venture capital funding including $24 million equity financing led by the Clermont Group. Used to enhance drug discovery programs and develop the AI-driven medicinal chemistry platform.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractEnterprise pharmaceutical partnerships

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

PostEra product offering

Product offering

Core offering

PostEra develops and applies Proton, its proprietary end-to-end machine learning platform for medicinal chemistry, to accelerate small molecule drug discovery. Through the platform the company runs co-discovery collaborations with major pharmaceutical companies (Pfizer, Amgen) and government agencies (NIH) and advances a wholly-owned preclinical pipeline in women's health (PCOS, reproductive endocrinology, fertility). Revenue is generated via multi-year partnerships with upfront payments, milestones, and royalties, supplemented by government grants.

Product overview

PostEra operates as an AI-driven biopharmaceutical company built around its Proton Platform—an end-to-end machine learning platform for medicinal chemistry. The company advances drug discovery through two channels: (1) a wholly-owned internal pipeline targeting women's health indications (PCOS, reproductive endocrinology, fertility), and (2) partnered programs with major pharmaceutical companies (Pfizer, Amgen, NIH) using Proton to discover small molecule therapeutics across oncology, obesity, antivirals, and antibody-drug conjugates. PostEra also led COVID Moonshot, the world's largest open-science drug discovery initiative. The company has secured over $1 billion in partnerships and is backed by Y Combinator.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proton Platform End-to-end AI platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary data with chemistry foundation models to design molecules, applies state-of-the-art synthesis planning to ensure reliable synthetic routes, and uses active learning methodologies to gather informative data at each cycle. Used by PostEra both to run partnered co-discovery programs with biopharma and to advance the company's internal drug pipeline.
  • COVID Moonshot Open-science, community-driven antiviral drug discovery program using PostEra's AI capabilities to crowdsource compound design, synthesis, and testing for COVID-19 therapeutics. Demonstrates the application of Proton outside of conventional biopharma partnerships and produces openly shared data for the research community.

Quantifiable outcome

  • One AI Lab program achieved its first scientific stage gate 40% faster than initially forecasted
  • +1 more outcomes

Companies that use PostEra

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

PostEra technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

PostEra partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • PfizerflagshipStrategic or Co-development Partner · 7 January 2025Expanded AI drug discovery collaboration to $610 million total deal value, adding antibody-drug conjugates (ADCs) to the partnership. Includes AI Lab formed in 2021 for multi-target collaboration and additional ADC programs in 2025. PostEra uses its Proton platform to accelerate multiple preclinical drug discovery programs with additional payments and milestones. One program achieved first stage gate 40% faster than forecasted; Pfizer nominated a third target into the AI Lab in 2024.
  • AmgencoreStrategic or Co-development Partner · 1 January 2023Multi-program agreement as part of PostEra's $1 billion+ in AI drug discovery collaborations. Collaboration focused on small molecule drug discovery using PostEra's Proton platform.
  • NIH (National Institutes of Health)coreStrategic or Co-development Partner · 1 May 2022Multi-year AI-driven drug discovery collaboration for antiviral therapeutics with $68 million initial funding. The initiative aims to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.
  • Oxford UniversityminorStrategic or Co-development PartnerListed as a Drug Discovery Partner on PostEra's website, indicating academic collaboration for drug discovery research.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

PostEra competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

PostEra social profiles

Digital presence

PostEra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PostEra leadership team

Management profile

Number of profiles

Profiles27 records

PostEra funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PostEra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PostEra

What does PostEra do?

PostEra develops and applies Proton, its proprietary end-to-end machine learning platform for medicinal chemistry, to accelerate small molecule drug discovery. Through the platform the company runs co-discovery collaborations with major pharmaceutical companies (Pfizer, Amgen) and government agencies (NIH) and advances a wholly-owned preclinical pipeline in women's health (PCOS, reproductive endocrinology, fertility). Revenue is generated via multi-year partnerships with upfront payments, milestones, and royalties, supplemented by government grants.

Is PostEra a public or private company?

PostEra is a private company. It is classified as venture growth investor backed and is currently operating.

When was PostEra founded?

PostEra was founded in 2019. It employs 11 to 50 people.

Where is PostEra based?

PostEra is headquartered in Boston, United States, in the North America region.

How does PostEra make money?

Three revenue lines are on record. Pharmaceutical Partnerships are the primary driver. The others are government Research Grants and equity Financing.

Does PostEra have an API?

No public API is recorded for PostEra.

What industry is PostEra in?

PostEra's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePostEra’s Fertility programs acquired by EMD Serono, Inc.EMD Serono acquired PostEra's two fertility programs: FSHR and LHCGR agonists. The programs are in preclinical development, with the LHCGR agonist showing potential as an oral alternative to injectable hCG. EMD Serono will assume sole responsibility for their development and commercialization.PR NewswirePostEra's Fertility programs acquired by EMD Serono, Inc.EMD Serono acquired PostEra's two fertility programs: FSHR and LHCGR agonists, developed with its AI platform Proton. The programs are in preclinical development, with the LHCGR agonist showing potential as an oral alternative to injectable hCG. EMD Serono will assume sole responsibility for their development and commercialization.PfizerHow AI Is Already Reshaping Cancer CarePfizer has deployed AI across its oncology operations, using machine learning to identify cancer patients eligible for clinical trials and partnering with PostEra to design antibody-drug conjugates for cancer treatment. The company reports a 40% reduction in clinical study report draft time through its Document Generation ecosystem and aims to increase trial enrollment rates by more than 20%. AI is enabling faster patient identification and more precise molecular-level drug design, representing a shift from computational biology's decades-long development in oncology toward actionable healthcare applications.YahooFactbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelinesPharmaceutical companies are increasingly adopting artificial intelligence to accelerate R&D, with industry forecasts suggesting machine learning could halve early-stage development timelines and costs within three to five years. A comprehensive factbox details dozens of AI-related partnerships announced from 2025 through early 2026, including major transactions such as Novartis acquiring Avidity Biosciences for approximately $12 billion in cash to strengthen its xRNA and neuromuscular portfolio. Notable individual deals include AstraZeneca's up-to-$5.2 billion partnership with CSPC Pharmaceutical for oral drug candidates and Pfizer's $610 million deal with PostEra for AI-powered ADC payload design.740ThefanFactbox-Pharma sector doubles down on AI amid hopes of slashing costs, timelinesPharmaceutical companies are increasingly adopting artificial intelligence to accelerate R&D, with industry forecasts predicting that machine-learning tools could halve early-stage development timelines and costs within three to five years. A factbox lists major AI-related partnerships announced from 2025 through early 2026, including Pfizer's $610 million deal with PostEra, AstraZeneca's up to $3.6 billion partnership with CSPC Pharmaceutical, Novartis's ~$12 billion acquisition of Avidity Biosciences, and Eli Lilly's multiple collaborations with NVIDIA and other AI firms. The partnerships span target discovery, molecule design, clinical-trial automation, and drug development acceleration across major global pharmaceutical players.Chemical & Engineering NewsHow PostEra designs drugs from codePostEra, a computational drug design startup, has secured over $1 billion in collaborative funding from Pfizer and Amgen to utilize its AI tools for discovering new small-molecule drugs. The company is now shifting its strategy to develop its own drug candidates in-house, focusing on women's health conditions such as polycystic ovarian syndrome and fertility issues. PostEra plans to begin human testing of two of these internal programs next year.CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsPostEra has expanded its AI-powered drug discovery collaboration with Pfizer to $610 million, adding a new partnership in antibodies and antibody-drug conjugates (ADCs) alongside an extension of the existing $260 million AI Lab collaboration. PostEra will receive a $12 million upfront payment with eligibility for additional milestone payments and royalties on approved products. The expansion builds on three years of successful collaboration where scientists from both companies advanced multiple small molecule programs, and validates PostEra's Proton AI platform for accelerating preclinical milestones.PromptloopWhat Does PostEra Do? AI-Powered Drug Discovery ExplainedPostEra is an AI-driven biopharma company that uses machine learning to accelerate medicinal chemistry and drug discovery, partnering with major pharmaceutical firms like Amgen and Pfizer. The company notably led the COVID Moonshot initiative and holds agreements with the NIH to optimize small molecule development. This overview highlights PostEra's role in reducing drug development timelines and its competitive position against other AI drug discovery entities.LinkedInPharma Deals for TechBio: Part IThe article provides strategic advice for biotech founders on structuring large technology collaboration deals with major pharmaceutical companies to validate platforms and secure funding. It outlines five core benefits of such partnerships, including platform validation, differentiation, front-end economics, back-end economics, and long-term platform improvement. The author uses examples from companies like PostEra, Exscientia, Pfizer, and Amgen to illustrate the potential financial and operational impacts of these agreements.BioPharmaTrendPostEra and Pfizer Expand $610M Partnership for AI-Driven ADC DevelopmentPostEra and Pfizer have expanded their partnership to a total value of $610 million, adding a new initiative for AI-driven Antibody-Drug-Conjugate (ADC) development alongside an expansion of their existing small molecule collaboration. The agreement includes a $12 million upfront payment for PostEra, with additional milestone payments and royalties tied to future product approvals. This expansion builds on the success of their previous AI Lab collaboration, which previously advanced several small molecule programs to nomination.